OPIANT PHARMACEUTICALS, INC. Annual Nonoperating Income (Expense) in USD from 2012 to 2021

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Opiant Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2012 to 2021.
  • Opiant Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2022 was -$278K, a 48.8% increase year-over-year.
  • Opiant Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2022 was -$1.51M, a 14% increase year-over-year.
  • Opiant Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2021 was -$2.12M, a 4505% decline from 2020.
  • Opiant Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2020 was -$46.1K, a 109% decline from 2019.
  • Opiant Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2019 was $504K, a 987% increase from 2018.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2021 -$2.12M -$2.08M -4505% Jan 1, 2021 Dec 31, 2021 10-K 2022-03-15
2020 -$46.1K -$550K -109% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-15
2019 $504K +$458K +987% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-04
2018 $46.4K -$21.6K -31.8% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-04
2017 $68K +$144K Jan 1, 2017 Dec 31, 2017 10-K 2019-03-21
2016 -$75.8K +$62.6K +45.2% Aug 1, 2015 Jul 31, 2016 10-KT 2018-03-07
2015 -$138K +$41.1K +22.9% Aug 1, 2014 Jul 31, 2015 10-K 2016-10-28
2014 -$179K +$191K +51.6% Aug 1, 2013 Jul 31, 2014 10-K 2015-10-26
2013 -$371K -$285K -334% Aug 1, 2012 Jul 31, 2013 10-K 2014-10-27
2012 -$85.5K Aug 1, 2011 Jul 31, 2012 10-K 2013-10-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.